Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1984 Oct;18(1):1–4. doi: 10.1007/BF00205391

Reflections on tumor origin, immunogenicity, and immunotherapy

David W Weiss 1,✉
PMCID: PMC11039076  PMID: 6386142

The content is available as a PDF (515.7 KB).

References

  • 1.Baldwin RW, Price MR. Immunobiology of rat neoplasia. Ann NY Acad Sci. 1976;276:3. doi: 10.1111/j.1749-6632.1976.tb41632.x. [DOI] [PubMed] [Google Scholar]
  • 2.Brosman SA. Experience with BCG in patients with superficial bladder cancer. J Urol. 1982;128:27. doi: 10.1016/s0022-5347(17)52736-6. [DOI] [PubMed] [Google Scholar]
  • 3.Cabilly S, Riggs AD, Pande H, Shively JE, Holmes WmE, Rey M, Perry LJ, Wetzel R, Heyneker HL (1984) Recombinant antibodies. I. Generation of antibody activity from immunoglobulin peptide chains produced in bacteria. Proc Natl Acad Sci USA (in press) [DOI] [PMC free article] [PubMed]
  • 4.Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallie BL, Murphree AL, Strong LC, White RL. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature. 1983;305:779. doi: 10.1038/305779a0. [DOI] [PubMed] [Google Scholar]
  • 5.Epstein LB. Interferon as a model lymphokine. Fed Proc. 1981;40:56. [PubMed] [Google Scholar]
  • 6.Folkman J. Tumor angiogenesis. Adv Cancer Res. 1974;19:331. doi: 10.1016/s0065-230x(08)60058-5. [DOI] [PubMed] [Google Scholar]
  • 7.Foulds L. The natural history of cancer. J Chronic Dis. 1958;8:2. doi: 10.1016/0021-9681(58)90039-0. [DOI] [PubMed] [Google Scholar]
  • 8.Heppner GH, Miller BE. Tumor heterogeneity: biological implications and therapeutic consequences. Cancer Metastasis Rev. 1983;2:5. doi: 10.1007/BF00046903. [DOI] [PubMed] [Google Scholar]
  • 9.Hewitt HB. Book review. Br J Cancer. 1980;42:627. [Google Scholar]
  • 10.Hewitt HB, Blake ER, Walder AS. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer. 1976;33:241. doi: 10.1038/bjc.1976.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Israël L, Edelstein R. In vivo and in vitro studies on nonspecific blocking factors of host origin in cancer patients. Role of plasma exchange as an immunotherapeutic modality. Isr J Med Sci. 1978;14:105. [PubMed] [Google Scholar]
  • 12.Kedar E, Weiss DW. The in vitro generation of effector lymphocytes and their employment in tumor immunotherapy. Adv Cancer Res. 1983;38:171. doi: 10.1016/s0065-230x(08)60190-6. [DOI] [PubMed] [Google Scholar]
  • 13.Kedar E, Chriqui-Zeira E, Weiss DW, Kyriazis AP (1984) Immunotherapy of murine and human tumors growing in mice with lymphokines and IL-2 propagated lymphocytes. J Biol Resp Mod (in press) [PubMed]
  • 14.Klein B, Devens B, Deutsch O, Ahituv A, Frenkel S, Kobrin BJ, Naor D. Isolation of immunogenic and suppressogenic determinants of the nonimmunogenic YAC tumor and the change in its immunogenic repertoire after in vitro cultivation. Transplant Proc. 1981;13:790. [PubMed] [Google Scholar]
  • 15.Klein G, Klein E. Immune surveillance against virus induced tumors and nonrejectability of spontaneous tumors: Contrasting consequences of host versus tumor evolution. Proc Natl Acad Sci USA. 1977;74:2121. doi: 10.1073/pnas.74.5.2121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Klein G, Klein E (1984) Oncogene activation and tumor progression. (in press) [DOI] [PubMed]
  • 17.Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature. 1983;304:596. doi: 10.1038/304596a0. [DOI] [PubMed] [Google Scholar]
  • 18.Logan J, Cairns J. The secrets of cancer. Nature. 1982;300:104. doi: 10.1038/300104a0. [DOI] [PubMed] [Google Scholar]
  • 19.Markson Y, Weiss DW, Weiss O, Doljanski F (1984) Shedding of cell surface antigens from human colon carcinoma cells growing in athymic mice. Human Immunol (in press) [DOI] [PMC free article] [PubMed]
  • 20.Morton DL (1984) Tumor debulking as immunotherapeutic measure. Trans Proc (in press)
  • 21.Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194:23. doi: 10.1126/science.959840. [DOI] [PubMed] [Google Scholar]
  • 22.Ruley HE. Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture. Nature. 1983;304:602. doi: 10.1038/304602a0. [DOI] [PubMed] [Google Scholar]
  • 23.Schmitt M, Daynes RA. Heterogeneity of tumorigenicity phenotype in murine tumors. Transplantation. 1982;33:387. doi: 10.1097/00007890-198204000-00009. [DOI] [PubMed] [Google Scholar]
  • 24.Sulitzeanu D (1984) Human cancer-associated antigens: Present status and implications for immunodiagnosis. Adv Cancer Res (in press) [DOI] [PubMed]
  • 25.Sulitzeanu D, Weiss DW. Antigen and immunogen. A question of terminology. Cancer Immunol Immunother. 1981;11:291. [Google Scholar]
  • 26.Terman DS, Young JB, Sherer WT, Ayus C, Lehande D, Mattioli C, Espada R, Howell JF, Yamamoto T, Zaleski HI, Miller L, Frommer P, Feldman L, Henry JF, Tillquist R, Cook G, Daskal Y. Preliminary observations of the effects on breast adenocarcinoma of plasma perfused over immobilized protein A. N Engl J Med. 1981;305:1195. doi: 10.1056/NEJM198111123052006. [DOI] [PubMed] [Google Scholar]
  • 27.Waters H, editor. The handbook of cancer immunology, vol 2: Cellular escape from immune destruction. New York: Garland STPM Press; 1978. [Google Scholar]
  • 28.Weiss DW. Immunotherapy of Human Cancer, University of Texas System Cancer Center 22nd Annual Clinical Conference on Cancer. New York: Raven; 1978. Animal models of cancer immunotherapy: Some considerations; pp. 101–109. [Google Scholar]
  • 29.Weiss DW. Tumor antigenicity and approaches to tumor immunotherapy. An outline. Curr Top Microbiol Immunol. 1980;89:1. [PubMed] [Google Scholar]
  • 30.Weiss DW (1984a) Tumor origin, progression, immunogenicity, and immunotherapy. Transplant Proc (in press) [PubMed]
  • 31.Weiss DW. Nonspecific immunity and cancer. In: Wayne LG, Kubica JP, editors. The mycobacteria — A sourcebook. New York: Dekker; 1984. [Google Scholar]
  • 32.Zimber C, Ben-Efraim S, Grover NB, Weiss DW. Prevention by the MER tubercle bacillus fraction of immuno-suppression induced by cancer chemotherapeutic agents. III. Contact hypersensitivity to dinitrofluorobenzene in mice treated with methotrexate, 5-fluorouracil, or cyclophosphamide, or exposed to dinitrobenzenesulfonate. Cancer Immunol Immunother. 1981;10:147. [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES